CytomX Therapeutics Inc (CTMX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $444.73M
Last updated: Nov 17, 2026 at 11:04 AM ET
CytomX Therapeutics Inc (CTMX) Competitors
The companies most similar to CytomX Therapeutics are Cullinan Oncology LLC (CGEM), CorMedix (CRMD) and Candel Therapeutics (CADL). By market cap, CytomX Therapeutics ranks 8th of the 13 companies on this page; Kura Oncology (KURA) is the largest at $713.90M.
Peer Comparison
CTMX's ROIC of -32.8% is below the peer median of -14.9%, and its revenue growth of -71.7% is below the median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| CytomX Therapeutics (CTMX) | $444.73M | N/A | 31.0x | 0.0% | -32.8% | -71.7% | 0.00% |
| Cullinan Oncology LLC (CGEM) | $667.39M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| CorMedix Inc (CRMD) | $370.64M | 6.3x | 0.9x | 15.5% | 13.9% | -47.7% | 0.00% |
| Candel Therapeutics Inc (CADL) | $486.37M | N/A | N/A | 0.0% | -43.5% | 0.0% | 0.00% |
| Immix Biopharma Inc (IMMX) | $657.09M | N/A | N/A | 0.0% | -14.9% | 0.0% | 0.00% |
| Puma Biotechnology Inc (PBYI) | $401.70M | 15.0x | 1.6x | 10.3% | N/A | 1.1% | 0.00% |
| Gyre Therapeutics Inc. (GYRE) | $471.74M | N/A | 3.8x | -22.7% | N/A | 0.7% | 0.00% |
| Contineum Therapeutics, Inc. Class A Common Stock (CTNM) | $387.16M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Tevogen Bio Holdings Inc. (TVGN) | $406.59M | N/A | N/A | 0.0% | 2022.8% | 0.0% | 0.00% |
| Fulcrum Therapeutics Inc (FULC) | $287.96M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Phathom Pharmaceuticals Inc (PHAT) | $492.63M | N/A | 1.8x | -30.2% | 11.4% | 71.1% | 0.00% |
| Kura Oncology Inc (KURA) | $713.90M | N/A | 8.0x | 0.0% | -1125.3% | 10.1% | 0.00% |
| Olema Pharmaceuticals Inc (OLMA) | $662.30M | N/A | N/A | 0.0% | -53.8% | 0.0% | 0.00% |
| Peer median | $479.05M | 10.7x | 1.8x | 0.0% | -14.9% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to CytomX Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Cullinan Oncology LLC (CGEM) | Cullinan Management, Inc., a biopharmaceutical company, is focused on developing a line of targeted oncology and immuno-oncology therapies for cancer patients... | CGEM competitors |
| CorMedix Inc (CRMD) | CorMedix Inc., a biopharmaceutical company, focuses on developing and marketing therapeutic products for the prevention and treatment of infectious... | CRMD competitors |
| Candel Therapeutics Inc (CADL) | Candel Therapeutics Inc. is a pioneering biotechnology company focused on revolutionizing cancer treatment through its proprietary oncolytic virus platform... | CADL competitors |
| Immix Biopharma Inc (IMMX) | Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology... | IMMX competitors |
| Puma Biotechnology Inc (PBYI) | Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care in the United States... | PBYI competitors |
| Gyre Therapeutics Inc. (GYRE) | Gyre Therapeutics Inc. is a pioneering biopharmaceutical company at the forefront of developing advanced therapies for rare and complex diseases. | GYRE competitors |
| Contineum Therapeutics, Inc. Class A Common Stock (CTNM) | Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies... | CTNM competitors |
| Tevogen Bio Holdings Inc. (TVGN) | Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology... | TVGN competitors |
| Fulcrum Therapeutics Inc (FULC) | Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products to improve the lives of patients with genetically defined... | FULC competitors |
| Phathom Pharmaceuticals Inc (PHAT) | Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. | PHAT competitors |
| Kura Oncology Inc (KURA) | Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops drugs for the treatment of cancer in the United States. | KURA competitors |
| Olema Pharmaceuticals Inc (OLMA) | Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development... | OLMA competitors |
Frequently Asked Questions About CTMX
Who are CytomX Therapeutics' main competitors?
The companies most similar to CytomX Therapeutics include Cullinan Oncology LLC (CGEM), CorMedix (CRMD), Candel Therapeutics (CADL), Immix Biopharma (IMMX) and Puma Biotechnology (PBYI), listed from the closest match.
Who is CytomX Therapeutics' biggest competitor?
Kura Oncology (KURA) is the largest of the similar companies at $713.90M; Cullinan Oncology LLC (CGEM) is the closest match by business profile, size, sector and industry.
How does CTMX stock compare with its competitors?
CTMX's P/S is 31.0x against a peer median of 1.8x; its net margin is 0.0% against a peer median of 0.0%.
Which of CytomX Therapeutics' competitors pays a higher dividend?
CytomX Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is CytomX Therapeutics bigger than its competitors?
No. CytomX Therapeutics is 8th by market cap among the 13 companies on this page; the largest is Kura Oncology (KURA) at $713.90M.
CTMX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors